- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01132430
Motivational Interviewing for Medication Adherence in Asthma
9. februar 2018 oppdatert av: Simon Bacon, Hopital du Sacre-Coeur de Montreal
Impact of a Motivational Interviewing Intervention on Medication Adherence in Patients With Asthma
The high burden of asthma appears to be related to poor asthma control, which is associated with more frequent asthma symptoms, greater bronchodilator use and functional impairment, and worse pulmonary function.
Despite the availability of effective treatments, more than 58% of asthmatics are poorly controlled.
Daily adherence to inhaled corticosteroid (ICS) regimens is considered by experts to be one of the most important behavioral factors linked to achieving optimal asthma control.
However, there is a paucity of research on interventions specifically designed to improve ICS adherence among adult asthmatics.
The vast majority of intervention studies to date used atheoretical interventions to target behavior change, relying mainly upon educational approaches which have been criticised for "failing to translate knowledge into action."
This may be due to the fact that most education-based approaches do not specifically address or help patients overcome ambivalence about behavior change, which is necessary for ensuring daily adherence.
Motivational interviewing (MI) is a client-centred intervention that focuses on enhancing intrinsic motivation to change a particular behavior, and exploring and resolving ambivalence about behavior change.
Brief MI sessions (e.g., 1-5 x 15-30 minute sessions) have been shown to improve a variety of health behaviors (e.g., reduce alcohol consumption, improve dietary habits, increase exercise behaviour, and improve medication adherence) and health outcomes (reduce blood pressure, body mass index, and cholesterol levels).
However, no studies to date have assessed the efficacy of using MI to improve ICS adherence in asthmatics.
This study aims to assess the efficacy of using MI to improve daily medication (ICS) adherence in a sample of poorly controlled, non-adherent asthmatics.
It is hypothesized that patients randomized to the MI condition will exhibit significantly improved ICS adherence at 6 and 12-months post-intervention, independent of baseline levels and covariates, relative to patients randomized to the usual care control condition.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
50
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Quebec
-
Montreal, Quebec, Canada, H4J 1C5
- Hôpital du Sacré-Cœur de Montréal
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Patients 18 years and older
- Primary diagnosis of moderate-severe persistent asthma (as per GINA)
- Prescribed inhaled corticosteroid medication (min dose of 250 µg fluticasone equivalent per day) for at least 12 consecutive months
- Uncontrolled asthma (≤ 19 on the Asthma Control Test)
- Covered by a drug insurance plan (e.g., RAMQ)
- Non-adherent to ICS medication (based on having filled less than 30% of their prescriptions over the last year)
- Able to speak English or French.
Exclusion Criteria:
- Any other medical condition that confers greater illness morbidity than asthma (e.g., active cancer)
- Severe psychopathology (e.g., schizophrenia)
- Apparent cognitive or language deficit
- Are or plan to become pregnant or move outside of Quebec over the course of the study.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Usual care
Standard medical care within 4-6 week period
|
Standard medical care within 4-6 week period
|
|
Eksperimentell: Motivational interviewing
Brief MI sessions within 4-6 week period
|
Brief MI 3x30 minute sessions within 4-6 week period
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Inhaled corticosteroid adherence
Tidsramme: 12 months post-intervention
|
measured according to the following validated equation: # of treatment days (based on the # of canisters filled at the pharmacy x the duration of each prescription) divided by the # of prescription days (# of days the patient is expected to be taking his/her medication)
|
12 months post-intervention
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Inhaled corticosteroid adherence
Tidsramme: 6 months post-intervention
|
measured according to the following validated equation: # of treatment days (based on the # of canisters filled at the pharmacy x the duration of each prescription) divided by the # of prescription days (# of days the patient is expected to be taking his/her medication)
|
6 months post-intervention
|
|
Asthma Control Questionnaire (Juniper)
Tidsramme: 12 months post-intervention, with preliminary data collected at 6 months
|
12 months post-intervention, with preliminary data collected at 6 months
|
|
|
Asthma Control Test
Tidsramme: 12 months post-intervention, with preliminary data collected at 6 months
|
12 months post-intervention, with preliminary data collected at 6 months
|
|
|
Asthma Self-Efficacy Scale (Tobin)
Tidsramme: 12 months post-intervention, with preliminary data collected at 6 months
|
12 months post-intervention, with preliminary data collected at 6 months
|
|
|
Asthma Quality of Life Questionnaire (Juniper)
Tidsramme: 12 months post-intervention, with preliminary data collected at 6 months
|
12 months post-intervention, with preliminary data collected at 6 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. juni 2008
Primær fullføring (Faktiske)
1. mars 2013
Studiet fullført (Faktiske)
1. mars 2013
Datoer for studieregistrering
Først innsendt
27. mai 2010
Først innsendt som oppfylte QC-kriteriene
27. mai 2010
Først lagt ut (Anslag)
28. mai 2010
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
13. februar 2018
Siste oppdatering sendt inn som oppfylte QC-kriteriene
9. februar 2018
Sist bekreftet
1. juli 2015
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- MBMC001
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .